Navigation Links
Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer
Date:5/15/2008

Phase II Data Presented at ASCO Showed Acceptable Tolerability Profile,

with Low Incidence of Grade 3 and 4 Neuropathy

WOODCLIFF LAKE, N.J., May 15 /PRNewswire/ -- The investigational chemotherapeutic agent eribulin mesylate (E7389) demonstrated activity in a heavily pretreated population of women with locally advanced or metastatic breast cancer, according to results of a multi-center Phase II clinical trial. The study also suggests that eribulin mesylate has a manageable tolerability profile, with a low incidence of Grade 3 (severe) and no Grade 4 (disabling or life-threatening) neuropathy. These data (abstract #1084) will be presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) on Monday, June 2 from 2 to 6 p.m. at S Hall A1 of McCormick Place.

"The anti-tumor activity of eribulin mesylate, as observed in this study, is encouraging, given the limited treatment options for women with advanced breast cancer who have previously received multiple lines of therapy," said lead investigator Linda T. Vahdat, MD, of Weill Cornell Medical College in New York. "The subjects in this trial had received a median of four prior chemotherapy regimens that included an anthracycline, a taxane and capecitabine."

About Study 211

Study 211 is a Phase II, open-label, single-arm study evaluating the efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer who had received an anthracycline, a taxane and capecitabine as prior therapy, and who were refractory to their last chemotherapy regimen, as documented by progression on or within six months of that therapy.

Of 299 patients enrolled in the study, 291 were treated with eribulin mesylate. The median age of those patients was 56 years (range: 26-80 years). Eribulin mesylate was administered at a dose of 1.4mg/m2 as a 2- to 5-minute intravenous infusion on Days 1 and 8 of a 21-day cycle. Patients receiv
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
2. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
3. Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting
4. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
5. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
6. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
7. Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
8. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
9. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2014)... , September 14, 2014 ... EMITF ) announced today further to the ... 2014 (the "Company,s Previous Reports"), that it was informed ... of US$ 12.5 million by  Shanghai GEOC Hengtong Investment ... Group").In the framework of the present investment round in ...
(Date:9/12/2014)... DUBLIN, Ireland , September ... ,Research and Markets ( ... addition of the  "Global Pipeline ... Drugs (Tedizolid Phosphate, Ceftolozane/Tazobactam, Ceftazidime/Avibactam, ... - Trends and Forecast to ...
(Date:9/12/2014)... September 12, 2014 The ... [Beverages (Alcoholic, CSD, Sports & Energy Drinks, Others), ... Meat & Seafood)], by Material (Aluminum & Steel) ... defines and segments the Food & Beverage Metal ... application in terms of volumes and values. The ...
Breaking Medicine Technology:Elbit Imaging Ltd. Announces Investment of US$ 12.5 Million in Insightec by Shanghai GEOC Hengtong Investment Limited Partnership and Fortune China Limited 2Elbit Imaging Ltd. Announces Investment of US$ 12.5 Million in Insightec by Shanghai GEOC Hengtong Investment Limited Partnership and Fortune China Limited 3Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs (Tedizolid Phosphate, Ceftolozane/Tazobactam, Ceftazidime/Avibactam, Amikacin Inhale, Plazomicin, and Synflorix) - Trends and Forecast to 2020 2Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs (Tedizolid Phosphate, Ceftolozane/Tazobactam, Ceftazidime/Avibactam, Amikacin Inhale, Plazomicin, and Synflorix) - Trends and Forecast to 2020 3Food & Beverage Metal Cans Market Worth $49.20 Billion by 2019 2Food & Beverage Metal Cans Market Worth $49.20 Billion by 2019 3Food & Beverage Metal Cans Market Worth $49.20 Billion by 2019 4
... International, Inc.,(Nasdaq: DATA ), a technology and services ... industry, today reported its,operating results for the first quarter ... 31, 2008, revenue decreased,approximately 41% to $2,088,000 and the ... share on both a basic and diluted basis. These,results ...
... the treatment of ... schizophrenia and bipolar I disorder, WASHINGTON, May 8 ... of asenapine clinical trials,from the Olympia program was presented at ... D.C., May 3-8. Data from,the studies, involving patients with bipolar ...
Cached Medicine Technology:DATATRAK International Reports First Quarter Results for 2008 2DATATRAK International Reports First Quarter Results for 2008 3DATATRAK International Reports First Quarter Results for 2008 4DATATRAK International Reports First Quarter Results for 2008 5DATATRAK International Reports First Quarter Results for 2008 6DATATRAK International Reports First Quarter Results for 2008 7Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 2Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 3Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 4Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 6Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 7
(Date:9/15/2014)... DC (PRWEB) September 15, 2014 ... payment initiatives that bring providers on board as ... member satisfaction. When bundled payment programs are designed ... financial incentives, incentivize hospitals to work collaboratively with ... procedure-specific tally. On Sept. 24, the Atlantic Information ...
(Date:9/15/2014)... More than 30 million additional Americans ... Care Act. This fact begs the question “are there ... reform and an aging population create a demand for ... are trying to stay on top of the anticipated ... 204 days to fill, according to the Association of ...
(Date:9/15/2014)... FL (PRWEB) September 15, 2014 (PRWEB) September 15, 2014 ... what’s not; what the startup business requirements are in ... the new business. , Speakers include industry professionals, such ... Health Center in Oakland,CA and cannabis business consultant ... , who are already successfully running legal marijuana businesses ...
(Date:9/14/2014)... Petersburg, FL (PRWEB) September 15, 2014 Skin ... external factors like sun damage and not moisturizing properly. However, ... if skin has been cared for. , Two main reasons ... 2) Loss of hyaluronic acid in the skin , During ... and both of these are responsible for important moisture retention ...
(Date:9/14/2014)... (PRWEB) September 14, 2014 Government ... growth of the patient handling equipment market , ... lucrative growth potential for the next five years. ... the rise in geriatric population and increasing lifestyle ... leading to increased disabilities. Further the market is ...
Breaking Medicine News(10 mins):Health News:Sept. 24 Webinar to Profile Geisinger Health System, BCBS of North Carolina’s Successful Bundled-Payment Programs 2Health News:Affordable Care Act Poses Challenge for Hospital Recruiters, with Nationwide Physician Shortage Looming in the Near Future 2Health News:How to Start And Run a Successful Legal Marijuana Business 2Health News:2 Reasons Skin Becomes Dryer with Age and What To Do About It, From Sublime Beauty® 2Health News:2 Reasons Skin Becomes Dryer with Age and What To Do About It, From Sublime Beauty® 3Health News:10.7% CAGR For Patient Handling Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:10.7% CAGR For Patient Handling Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:10.7% CAGR For Patient Handling Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4
... , ... (Vocus) December 8, 2008 -- Losing a child to the ... , it is a tragedy they have experienced firsthand. The nonprofit organization ... the flu or have had a child experience severe medical complications from ...
... 8 - 14; Urges Immunization into December, January and Beyond ... Dec. 8 Mothers -- often the family,s primary healthcare ... families vaccinated against influenza throughout the winter months and even ... American Lung Association as part of its Faces of ...
... suggests it,s a promising candidate as marker for metastasis ... that may contribute to the spread of breast cancer ... (called Menainv) is present in invasive cells within a ... biomarker for metastatic breast cancer, the scientists said. , ...
... Technologies(R), a leading,provider of radio frequency identification systems and ... Designed to allow,hospitals easier access to the Safe Place ... financing, this option is especially helpful,in today,s tight economy. ... to offer a new way for hospitals to implement ...
... Conn., Dec. 8 SearchMedica.com,( http://www.searchmedica.com/ ), the ... new Radiology search channel. The search,channel connects radiologists ... relevant online medical imaging resources. , ... medical professional at some point,no matter what their ...
... to keep,families healthy and make it easier to get a ... largest retail health,care clinic in the U.S., announced that they ... this Fall,s flu shot season. , ... (NYSE: CVS ), launched,an integrated campaign on Oct. ...
Cached Medicine News:Health News:For Kids, the Flu Can Be Severe, Even Deadly 2Health News:For Kids, the Flu Can Be Severe, Even Deadly 3Health News:Survey Shows Mothers See Value in Influenza Vaccination for Their Families Through the Winter and Spring 2Health News:Survey Shows Mothers See Value in Influenza Vaccination for Their Families Through the Winter and Spring 3Health News:Survey Shows Mothers See Value in Influenza Vaccination for Their Families Through the Winter and Spring 4Health News:Survey Shows Mothers See Value in Influenza Vaccination for Their Families Through the Winter and Spring 5Health News:Scientists ID Protein Aiding Breast Cancer Spread 2Health News:RF Technologies(R) Introduces Safe Place(R) Usage Program Financing for Its Infant Security, Pediatric Security and ED Safety Solutions 2Health News:RF Technologies(R) Introduces Safe Place(R) Usage Program Financing for Its Infant Security, Pediatric Security and ED Safety Solutions 3Health News:SearchMedica Launches Radiology Search Channel for Medical Professionals 2Health News:CVS/pharmacy and MinuteClinic Reach Goal of Delivering One Million Flu Vaccinations 2Health News:CVS/pharmacy and MinuteClinic Reach Goal of Delivering One Million Flu Vaccinations 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: